INTELLIGENT ONCOLOGY
choose a different vision
Recent Releases
CHOSA Unveils Predictive Data for Cisplatin Response in Lung Cancer
26, March 2025 – CHOSA today announced the expected release timeline for results from a blinded, retrospective study using its Drug Response Predictor to assess cisplatin efficacy in lung cancer. Check out our new press release
CHOSA Oncology Presented at Økonomisk Ugebrev Investor Conference
CHOSA Oncology was presented by our CCO Claus Frisenberg at the Økonomisk Ugebrev Investor Conference on April 23, where leading companies and investors gathered to explore innovation and strategic growth in life sciences.
CHOSA collaboration paving the way for integration into clinical guidelines
CHOSA has partnered with Professor Solange Peters and Professor Rolf Stahel in analysing high quality biopsies from the lung cancer SPLENDOUR Trial.
We provide a safe and more effective solution for patients in need of platin-treatment
Drug Response Predictor
Discover the future of cancer treatment with DRP® — the first-ever biomarker for cisplatin.
Our patented DRP® analyzes 205 key genes in a patient’s tumor to predict their response to cisplatin and carboplatin, enabling personalized treatment plans to oncology patients. We have shown that our innovative technology not only improves survival rates, but also enables doctors to avoid overtreatment of toxic platin to non-responsding patients.
LiPlaCis®
A new formulation of cisplatin in a liposome aimed for a solution to cisplatin treatment by targeting tumors directly, reducing harmful side effects. Using a specialized liposome delivery system, LiPlaCis® releases cisplatin precisely where it's needed most—at the tumor site—providing safer and more effective cancer care.
Key Opinion Leaders
We’re honored by the strong support of seven prominent Key Opinion Leaders (KOLs) in the fields of lung, breast, bladder, and endometrial cancer. Their endorsement enhances the credibility of our DRP® and advances our mission toward precision oncology.
“We need to figure out how to select the right treatment to the right patients. So that is where the future goes. We are leaving the concept of one size fits all.”
Dr. Fred Hirsch